These are reviewed studies whose abstracts concern Ovarian Cancer. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Ovarian Cancer. Most are early lab, animal, or small human studies, and findings often conflict.
ReviewInconclusiveLimited evidenceTier 4 · clinical
Therapeutic advances in medical oncology · Dec 2025 · review
epithelial ovarian cancerhigh-grade serous ovarian cancerovarian clear cell carcinomaendometrioid ovarian carcinomamucinous ovarian carcinomalow-grade serous ovarian carcinomaovarian carcinosarcoma
This review describes the main genomic subtypes of epithelial ovarian cancer and how those differences may help match patients to targeted therapies. It highlights PARP inhibitors, MAPK pathway inhibitors, cell cycle checkpoint inhibitors, immune checkpoint inhibitors, and antibody-drug conjugate approaches that are being investigated for specific ovarian cancer types. The article also notes that resistance to PARP inhibitors remains a problem and that more evidence is needed for effective combination therapies.
Key findings
- High-grade serous ovarian cancer is linked mainly to homologous recombination repair gene alterations such as BRCA1 and BRCA2.
- Ovarian clear cell carcinoma is associated with ARID1A and PIK3CA alterations; endometrioid ovarian carcinoma with PIK3CA and KRAS; mucinous ovarian carcinoma with CDKN2A and KRAS; and low-grade serous ovarian carcinoma with MAPK pathway genes such as BRAF and KRAS.
- PARP inhibitor therapy has improved survival for women with homologous recombination repair defects in high-grade serous ovarian cancer, but acquired resistance remains an issue.
- The review emphasizes that genomically targeted combination therapies are urgently needed and that some reported responses are preliminary.
Limitations: Review article only; no new experimental or clinical data presented in the abstract.; No quantitative outcomes or effect sizes are reported in the abstract.; The abstract is broad and does not provide trial-level details, sample sizes, or follow-up durations.; Some therapies discussed are preliminary and require further evidence..
The article is about ovarian cancer genomics and targeted therapies, not a single compound experiment.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 381
Lancet (London, England) · Jun 2025 · randomized, controlled, open-label phase 3 trial
Relacorilantplatinum-resistant ovarian cancerepithelial ovarian cancerprimary peritoneal cancerfallopian tube cancer This phase 3 randomized trial tested whether adding relacorilant to nab-paclitaxel helped women with platinum-resistant ovarian cancer. The combination improved progression-free survival and also showed a longer overall survival at an interim analysis. Side effects were similar between groups after accounting for nab-paclitaxel exposure, and no new safety signals were seen.
Reported effects: progression-free survival hazard ratio 0.7 [0.54–0.91], p p=0.0076, n=381 · progression-free survival median 6.54 mo [5.55–7.43], n=188 · +3 more
Studied with: nab-paclitaxel.
Key findings
- Progression-free survival was significantly longer with relacorilant plus nab-paclitaxel than with nab-paclitaxel alone.
- An interim overall survival analysis also favored the combination.
- Adverse events were similar across groups when adjusted for nab-paclitaxel exposure; no new safety signals were observed.
Limitations: Open-label design; Overall survival result was based on a planned interim analysis; Trial is ongoing; Funding from the drug manufacturer.
This study evaluated relacorilant as an added anticancer agent in platinum-resistant ovarian cancer.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Human trialTrialInconclusiveModerate evidenceTier 4 · clinical
Journal of gynecologic oncology · Jul 2024 · phase 3, randomized, 2-arm, open-label, global multicenter study protocol
Relacorilantadvanced platinum-resistant ovarian cancerrecurrent platinum-resistant high-grade serous epithelial ovarian cancerprimary peritoneal cancerfallopian tube cancer This paper describes the ROSELLA phase 3 trial, which is testing relacorilant plus nab-paclitaxel versus nab-paclitaxel alone in women with recurrent platinum-resistant ovarian and related cancers. The study is designed to see whether adding relacorilant improves progression-free survival and other outcomes, and it will also assess safety and patient-reported outcomes. The abstract does not report trial results, only the study plan.
Studied with: nab-paclitaxel.
Key findings
- ROSELLA is a phase 3, randomized, 2-arm, open-label, global multicenter study.
- Participants are assigned 1:1 to relacorilant plus nab-paclitaxel or nab-paclitaxel monotherapy.
- Primary endpoint is progression-free survival assessed by blinded independent central review.
- Secondary endpoints include overall survival, objective response rate, duration of response, clinical benefit rate at 24 weeks, and CA-125 response.
- The abstract reports no efficacy or safety results because it is a trial protocol.
Limitations: Protocol only; no outcomes or results are reported in the abstract.; No sample size is provided in the abstract.; No quantitative effect estimates are available.; Open-label design may introduce bias in some endpoints..
This is a phase 3 protocol in platinum-resistant ovarian cancer evaluating an anticancer combination.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewInconclusiveLimited evidenceTier 4 · clinical
Current treatment options in oncology · Dec 2023 · narrative review
ovarian carcinosarcomaovarian cancer
This review summarizes what is known about ovarian carcinosarcoma, a rare and aggressive ovarian cancer. It discusses risk factors, prognostic markers, and current treatment approaches such as surgery followed by platinum-based chemotherapy, while noting that immunotherapy and HRD testing may be useful in some patients. The article does not report new experimental results from a trial or laboratory study.
Key findings
- Ovarian carcinosarcoma is described as rare and aggressive, with median overall survival under 2 years.
- Poor prognostic factors include advanced stage, older age, lymph node metastasis, suboptimal cytoreduction, heterologous histology, and increased VEGF, p53, and WT1 expression.
- Main treatment approach is cytoreductive surgery followed by platinum-based chemotherapy.
- Immunotherapy is described as promising, and HRD testing may help personalize therapy.
Limitations: Narrative review rather than original research.; No new patient cohort, control group, or quantitative treatment effect data reported in the abstract.; Most evidence discussed is from case reports and small studies.; The abstract does not specify which therapies or biomarkers were evaluated in detail..
Provides an overview of ovarian carcinosarcoma epidemiology, prognosis, and treatment options rather than testing a specific compound.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialMixed resultsModerate evidenceTier 4 · clinicaln = 178
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Oct 2023 · three-arm, randomized, controlled, open-label phase II study
Relacorilantovarian cancerovarian epithelial carcinomaprimary peritoneal cancerfallopian tube cancerovarian carcinosarcoma This phase II study tested relacorilant added to nab-paclitaxel in women with recurrent platinum-resistant or refractory ovarian and related cancers. The intermittent relacorilant schedule improved progression-free survival and duration of response compared with nab-paclitaxel alone, while overall response rate was similar across groups. Side effects were broadly comparable between arms, and the study did not meet its prespecified statistical threshold after multiplicity adjustment.
Reported effects: PFS HR 0.66, p P = .038, n=178 · DOR HR 0.36, p P = .006, n=178 · +1 more
Studied with: nab-paclitaxel.
Key findings
- Intermittent relacorilant plus nab-paclitaxel improved PFS versus nab-paclitaxel monotherapy (HR 0.66; P = .038).
- Intermittent relacorilant plus nab-paclitaxel improved DOR versus nab-paclitaxel monotherapy (HR 0.36; P = .006).
- ORR was similar across arms.
- At the preplanned OS analysis, the OS HR was 0.67 with P = .066 for the intermittent arm versus nab-paclitaxel monotherapy.
- Continuous relacorilant plus nab-paclitaxel showed numerically improved median PFS but no significant improvement over monotherapy.
- Adverse events were comparable across study arms; common grade ≥3 events included neutropenia, anemia, peripheral neuropathy, and fatigue/asthenia.
Limitations: Phase II study with relatively small sample size.; Open-label design.; Primary end point did not reach statistical significance after protocol-prespecified Hochberg step-up multiplicity adjustment.; Median follow-up was limited for PFS and OS analyses.; Safety and efficacy were compared against nab-paclitaxel monotherapy, but the abstract does not provide detailed absolute event rates..
Relacorilant was studied as an add-on to chemotherapy in recurrent platinum-resistant ovarian cancer.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewTrialReported positiveModerate evidenceTier 4 · clinical
Drugs · Jul 2021 · review article summarizing drug development and approval
Fuzuloparibovarian cancerfallopian tube cancerprimary peritoneal cancersolid cancerspancreatic cancerbreast cancerprostate cancerlung cancer This review describes fuzuloparib, an oral PARP inhibitor, and its development leading to approval in China. The approval was for platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with a germline BRCA mutation after second-line or later chemotherapy. The abstract also notes that phase II and III trials are ongoing in other solid cancers.
Key findings
- Fuzuloparib is an orally active PARP inhibitor.
- It has been approved in China for platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with germline BRCA mutation after second-line or above chemotherapy.
- Phase II and III trials are investigating it in other solid cancers.
Limitations: Review article; no original study data in the abstract.; No efficacy or safety results are reported in the abstract.; No comparator, sample size, or quantitative outcomes are provided..
This is a drug approval review focused on fuzuloparib's use in ovarian and related cancers, not an experimental efficacy study.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 295
The Lancet. Oncology · May 2021 · double-blind, randomised, placebo-controlled, phase 3 trial
Olaparibovarian cancerhigh-grade serous ovarian cancerhigh-grade endometrioid ovarian cancerprimary peritoneal cancerfallopian tube cancer This phase 3 study tested olaparib tablets as maintenance therapy in people with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation. In the final analysis, the olaparib group had a longer median overall survival than the placebo group, but the difference did not reach conventional statistical significance. More serious side effects, including anemia, were reported with olaparib.
Reported effects: Median overall survival 51.7 mo [41.5–59.1], n=196 · Median overall survival 38.8 mo [31.4–48.6], n=99 · +1 more
Key findings
- Median overall survival was 51.7 months with olaparib versus 38.8 months with placebo.
- The hazard ratio for overall survival was 0.74 with a 95% CI of 0.54 to 1.00; p=0.054.
- Grade 3 or worse anemia occurred in 21% of patients receiving olaparib and 2% receiving placebo.
- Serious treatment-emergent adverse events occurred in 26% of patients receiving olaparib and 8% receiving placebo.
- Fatal treatment-emergent adverse events occurred in 4% of patients receiving olaparib; 6 deaths were judged treatment-related.
Limitations: Overall survival difference did not reach statistical significance (p=0.054).; Overall survival was unadjusted for subsequent PARP inhibitor therapy in 38% of placebo patients, which may confound interpretation.; Safety and efficacy are from a single randomized trial population with BRCA1/2-mutated platinum-sensitive relapsed ovarian cancer, limiting generalizability.; The abstract does not provide subgroup analyses or long-term quality-of-life outcomes..
Maintenance olaparib was evaluated for its effect on overall survival in relapsed BRCA1/2-mutated ovarian cancer.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 391
The New England journal of medicine · Dec 2018 · international randomized double-blind phase 3 trial
Olaparibadvanced ovarian cancerhigh-grade serous ovarian cancerendometrioid ovarian cancerprimary peritoneal cancerfallopian-tube cancer This randomized phase 3 trial tested olaparib as maintenance therapy after platinum-based chemotherapy in women with newly diagnosed advanced BRCA1/2-mutated ovarian, primary peritoneal, or fallopian-tube cancer. After a median follow-up of 41 months, women assigned to olaparib had a longer progression-free survival than those assigned to placebo. The abstract also reports more patients were free of disease progression and death at 3 years in the olaparib group. Adverse events were said to be consistent with the known toxic effects of olaparib.
Reported effects: Kaplan-Meier estimate of the rate of freedom from disease progression and from death at 3 years 60%, n=391 · hazard ratio for disease progression or death 0.3 [0.23–0.41], p <0.001, n=391
Studied with: platinum-based chemotherapy.
Key findings
- Olaparib maintenance was associated with a lower risk of disease progression or death than placebo.
- 3-year freedom from disease progression and death was higher with olaparib than placebo (60% vs. 27%).
- Adverse events were consistent with the known toxic effects of olaparib.
Limitations: Progression-free survival was the primary endpoint; overall survival is not reported in the abstract.; Follow-up was median 41 months, so longer-term outcomes are not fully described here.; Adverse events are summarized only briefly in the abstract..
Maintenance olaparib was evaluated in a randomized trial in newly diagnosed advanced BRCA1/2-mutated gynecologic cancers.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 484
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jun 2012 · randomized, double-blind, placebo-controlled phase III trial
Bevacizumabplatinum-sensitive recurrent epithelial ovarian cancerprimary peritoneal cancerfallopian tube cancer This phase III trial tested bevacizumab added to gemcitabine and carboplatin in people with platinum-sensitive recurrent ovarian, primary peritoneal, or fallopian tube cancer. The bevacizumab group had longer progression-free survival and a higher response rate than the placebo group. More high blood pressure and protein in the urine were seen with bevacizumab, but the study reported no new safety concerns overall.
Reported effects: PFS hazard ratio 0.484 [0.388–0.605], p < .0001, n=484 · median PFS 12.4 mo, n=484 · +3 more
Studied with: gemcitabine, carboplatin.
Key findings
- Bevacizumab plus gemcitabine/carboplatin improved progression-free survival versus gemcitabine/carboplatin plus placebo.
- Objective response rate and duration of response were also improved with bevacizumab.
- Grade 3 or higher hypertension and proteinuria were more frequent with bevacizumab.
Limitations: Progression-free survival was the primary endpoint; overall survival results are not reported in the abstract.; Safety follow-up details are limited in the abstract.; Adverse event reporting is summarized rather than fully detailed in the abstract..
This study evaluates bevacizumab as an added anticancer agent in recurrent gynecologic cancers.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text